MyFinsight
Home
Blog
About
something is missing
$31,867,075
Change in cash, cash
equivalents and restricted...
$26,634,510
(521.35%↑ Y/Y)
Canceled cashflow
$5,232,565
Accounts payable
$189,800
(217.45%↑ Y/Y)
Stock-based compensation
$103,193
(-59.59%↓ Y/Y)
Prepaid expenses and
other current and...
-$98,755
(71.60%↑ Y/Y)
Depreciation and
amortization
$5,746
(-47.08%↓ Y/Y)
Proceeds from issuance of
common stock
$500,068
(8.94%↑ Y/Y)
Net cash used in
operating activities
-$3,278,763
(51.51%↑ Y/Y)
Net cash provided by
financing activities
-$1,937,707
(-539.66%↓ Y/Y)
Net cash used in
investing activities
-$15,400
Effect of exchange rate
changes on cash, cash...
-$695
Canceled cashflow
$397,494
Canceled cashflow
$500,068
Net loss
-$3,591,304
(49.92%↑ Y/Y)
Common stock issuance
costs
$2,437,775
(13227.73%↑ Y/Y)
Purchases of property and
equipment
$15,400
Accrued expenses
-$82,000
(33.70%↑ Y/Y)
Foreign currency (gain)
loss
$2,953
(103.65%↑ Y/Y)
Back
Back
Cash Flow
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)
source: myfinsight.com